Skip to content
value.today
Mirna Therapeutics, Inc. logo

Mirna Therapeutics, Inc.

🇺🇸 Austin, Texas, USABiotechnologyFounded 2007
Total raised
$61 M
3 rounds on record
Latest round
$42 M
Mar 2015
First round on record
Aug 2011
Today
Went public
See the company page

Mirna Therapeutics, Inc. is listed today as Synlogic, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Mirna Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$80 MPrivate placement after listing$50 to $250 million

Mirna Therapeutics, Inc.: Private sale, Jun 2019

Investors in this round

1 investor had bought by the notice of Jun 18, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Mirna Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aoife Brennan · Executive Officer, Director
  • Todd Shegog · Executive Officer
  • Chau Khuong · Director
  • Edward Mathers · Director
  • Michael Powell · Director
  • Nick Leschly · Director
  • Patricia Hurter · Director
  • Peter Barrett · Director
  • Richard P. Shea · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Todd Shegog, Chief Financial Officer. Newest notice filed Jun 18, 2019. Read the notice at the SEC.

equity, optionsSEC
Mar 2015$42 MNo. 3$10 to $50 million

Mirna Therapeutics, Inc.: Raise no. 3, Mar 2015

Investors in this round

24 investors had bought by the notice of May 1, 2015: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Mirna Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$42 M of $45 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Casi DeYoung · Executive Officer
  • Jon Irvin · Executive Officer
  • Paul Lammers · Executive Officer, Director
  • Sinil Kim · Executive Officer
  • Clay Siegall · Director
  • Corey Goodman · Director
  • Ed Mathers · Director
  • Elaine Jones · Director
  • Larry Alleva · Director
  • Matthew Winkler · Director
  • Michael Powell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jon Irvin, Chief Financial Officer. Newest notice filed May 1, 2015. Read the notice at the SEC.

equitySEC
Oct 2012$17 MNo. 2$10 to $50 million

Mirna Therapeutics, Inc.: Raise no. 2, Oct 2012

Investors in this round

17 investors had bought by the notice of Nov 2, 2012: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Mirna Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $35 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$787,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ana V Ward · Executive Officer
  • Lynne V Hohlfeld · Executive Officer
  • Paul Lammers · Executive Officer, Director
  • Corey V Goodman · Director
  • Edward V Mathers · Director
  • Elaine V Jones · Director
  • Matthew M Winkler · Director
  • Michael M Powell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ferghana Securities, Inc. (CRD 43430) · New York, New YorkSold in CA, MD, NY, PA

Remarks in the notice

  • On fees: “Amount paid in connection with the initial closing.”

Signed by Lynne Hohlfeld, CFO and Secretary. Newest notice filed Nov 2, 2012. Read the notice at the SEC.

equitySEC
Aug 2011$2 MNo. 1Under $2 million

Mirna Therapeutics, Inc.: Raise no. 1, Aug 2011

Investors in this round

9 investors had bought by the notice of Aug 23, 2011: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Mirna Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ana C Ward · Executive Officer
  • Lynne S Hohlfeld · Executive Officer
  • Paul Lammers · Executive Officer, Director
  • Christopher D Earl · Director
  • Corey S Goodman · Director
  • Evan S Melrose · Director
  • Matthew M Winkler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lynne Hohlfeld, Chief Financial Officer & Secretary. Newest notice filed Aug 23, 2011. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Mirna Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).

    SEC Form D · Jun 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2019

Products and services#

No products or services of Mirna Therapeutics, Inc. are on record.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Mirna Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Matthew WinklerPersonnot statednot statedHeld Series A, B, C and D preferred stock, director (Form 3, 2015)SEC Form 3
Nea 14 GP, LTDCompanynot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
NEA Partners 14, L.P.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
New Enterprise Associates 14, L.P.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Pfizer IncFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Sofinnova Management VIII, L.L.C.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Sofinnova Venture Partners VIII, L.P.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Largest shareholders today

Institutions holding Synlogic, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Mirna Therapeutics, Inc.
NameRoleNamed in
Aoife BrennanExecutive officerJun 2019
Todd ShegogExecutive officerJun 2019
Casi DeYoungExecutive officerMay 2015
Jon IrvinExecutive officerMay 2015
Paul LammersExecutive officerMay 2015
Sinil KimExecutive officerMay 2015
Ana V WardExecutive officerNov 2012
Lynne V HohlfeldExecutive officerNov 2012
Ana C WardExecutive officerAug 2011
Lynne S HohlfeldExecutive officerAug 2011
Aoife BrennanDirectorJun 2019
Chau KhuongDirectorJun 2019
Edward MathersDirectorJun 2019
Michael PowellDirectorJun 2019
Nick LeschlyDirectorJun 2019
Patricia HurterDirectorJun 2019
Peter BarrettDirectorJun 2019
Richard P. SheaDirectorJun 2019
Clay SiegallDirectorMay 2015
Corey GoodmanDirectorMay 2015
Ed MathersDirectorMay 2015
Elaine JonesDirectorMay 2015
Larry AllevaDirectorMay 2015
Matthew WinklerDirectorMay 2015
Paul LammersDirectorMay 2015
Corey V GoodmanDirectorNov 2012
Edward V MathersDirectorNov 2012
Elaine V JonesDirectorNov 2012
Matthew M WinklerDirectorNov 2012
Michael M PowellDirectorNov 2012
Christopher D EarlDirectorAug 2011
Corey S GoodmanDirectorAug 2011
Evan S MelroseDirectorAug 2011

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.